Vita Life Sciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Vita Life Sciences şirketinin toplam hissedar öz sermayesi A$48.7M ve toplam borcu A$0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla A$68.0M ve A$19.3M dir. Vita Life Sciences 'in FAVÖK'ü A$12.1M faiz karşılama oranı -13.1 dur. Şirketin A$27.7M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

AU$0

Borç

Faiz karşılama oranı	-13.1x
Nakit	AU$27.75m
Eşitlik	AU$48.70m
Toplam yükümlülükler	AU$19.25m
Toplam varlıklar	AU$67.95m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: VLS 'nin kısa vadeli varlıkları ( A$56.3M ) kısa vadeli yükümlülüklerini ( A$19.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: VLS şirketinin kısa vadeli varlıkları ( A$56.3M ) uzun vadeli yükümlülüklerini ( A$236.0K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: VLS borçsuzdur.

Borcun Azaltılması: VLS şirketinin 5 yıl önce borç/öz sermaye oranı 9% iken borcu yok.

Borç Kapsamı: VLS un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: VLS şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Vita Life Sciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Non-Executive Chairman recently sold AU$654k worth of stock

New minor risk - Insider selling

MD & Director recently sold AU$1.9m worth of stock

Upcoming dividend of AU$0.06 per share

Vita Life Sciences Limited, Annual General Meeting, May 15, 2024

Final dividend increased to AU$0.06

Full year 2023 earnings released: EPS: AU$0.17 (vs AU$0.13 in FY 2022)

Less than half of directors are independent

Vita Life Sciences Limited Provides Earnings Guidance for the Full Year Ending December 31, 2023

Less than half of directors are independent

Upcoming dividend of AU$0.03 per share at 3.7% yield

Less than half of directors are independent

Vita Life Sciences Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, 6 October 2023

Vita Life Sciences Limited Appoints Peter Osborne as an Independent Non-Executive Director

No independent directors

No independent directors

No independent directors

No independent directors

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

Upcoming dividend of AU$0.033 per share at 3.9% yield

No independent directors

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

No independent directors

No independent directors

No independent directors

No independent directors

Vita Life Sciences Provides Earnings Guidance for the Full Year Ending 31 December 2022

No independent directors

Less than half of directors are independent

Vita Life Sciences Limited Announces Board Changes, Effective 30 September 2022

Upcoming dividend of AU$0.028 per share

Vita Life Sciences Limited Declares Fully Franked Interim Dividend for the Six Months Ended June 30, 2022, Payable on 7 October 2022

First half 2022 earnings released: EPS: AU$0.069 (vs AU$0.07 in 1H 2021)

Less than half of directors are independent

Less than half of directors are independent

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2022

Less than half of directors are independent

Upcoming dividend of AU$0.03 per share

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Less than half of directors are independent

Vita Life Sciences Limited Announces Dividend for Six Months Ended December 31, 2021, Payable on April 7, 2022

Less than half of directors are independent

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Upcoming dividend of AU$0.028 per share

First half 2021 earnings released: EPS AU$0.07 (vs AU$0.058 in 1H 2020)

Less than half of directors are independent

Less than half of directors are independent

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2021

Upcoming Dividend of AU$0.015 Per Share

Earnings released

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin